Document Detail


Celecoxib to prevent restenosis--results from the COREA-TAXUS trial.
MedLine Citation:
PMID:  18201156     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Celecoxib inhibits Akt, which is stimulated during restenosis. Cell and animal studies showed that celecoxib inhibited Akt stimulation and restenosis. Recently, the COREA-TAXUS (Effect of Celecoxib on Restenosis after Coronary Angioplasty with Taxus stent) trial was performed in subjects with angina or a positive-stress test receiving paclitaxel-eluting stents. The primary end point at 6 months was the in-stent, late luminal loss, which was 0.49 mm in the celecoxib-treated group; less than the 0.75 mm in the group not treated with celecoxib. The rate of revascularisation of the target lesion was lower in celecoxib-treated subjects (5%) than in the untreated subjects (15%). In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use.
Authors:
Sheila A Doggrell
Related Documents :
21107326 - Plasma heparin cofactor ii activity is inversely associated with left atrial volume and...
18208656 - Effects of sirolimus-eluting stent on calcified coronary lesions.
11786326 - Excimer laser coronary angioplasty and intracoronary radiation for in-stent restenosis:...
14727976 - Can angiotensin receptor antagonists prevent restenosis after stent placement?
21107326 - Plasma heparin cofactor ii activity is inversely associated with left atrial volume and...
22315956 - Proteomic profiling of acute coronary thrombosis reveals a local decrease of pedf in ac...
Publication Detail:
Type:  In Vitro; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  9     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-18     Completed Date:  2008-04-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  339-41     Citation Subset:  IM    
Affiliation:
RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia. sheila.doggrell@bigpond.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Coronary Restenosis / drug therapy,  prevention & control*
Female
Humans
Male
Pyrazoles / standards*,  therapeutic use*
Randomized Controlled Trials as Topic / methods,  trends*
Sulfonamides / standards*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fexofenadine in pediatrics: oral tablet and suspension formulations.
Next Document:  Democracy: the forgotten determinant of mental health.